Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-119236
Filing Date
2024-10-31
Accepted
2024-10-31 06:49:31
Documents
72
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q syrs-20240930.htm   iXBRL 10-Q 1722247
2 EX-31.1 syrs-ex31_1.htm EX-31.1 15673
3 EX-31.2 syrs-ex31_2.htm EX-31.2 15779
4 EX-32.1 syrs-ex32_1.htm EX-32.1 7708
5 EX-32.2 syrs-ex32_2.htm EX-32.2 7677
  Complete submission text file 0000950170-24-119236.txt   7895698

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT syrs-20240930.xsd EX-101.SCH 1478336
75 EXTRACTED XBRL INSTANCE DOCUMENT syrs-20240930_htm.xml XML 1186913
Mailing Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140
Business Address 35 CAMBRIDGE PARK DRIVE CAMBRIDGE MA 02140 617-744-1340
Syros Pharmaceuticals, Inc. (Filer) CIK: 0001556263 (see all company filings)

EIN.: 453772460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37813 | Film No.: 241412355
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)